Pascal Soriot’s been pushing for US-sized CEO pay for more than a decade. Now he’s finally getting it

Back in 2013, Pascal Soriot’s first full year at the helm of a tottering AstraZeneca, he landed a pay package worth about $5.5 million. By pharma CEO standards, it wasn’t much. And he likely wasn’t cheerful about the number.

Unlike just about every PR-conscious CEO in the industry, Soriot has from time to time voiced his displeasure about his pay, risking the inevitable grumbling that would come from everyone else in the company making far, far less.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Updated: Novo Nordisk’s semaglutide injection reduces cardiovascular events by 20% in vast SELECT trial

Novo Nordisk’s semaglutide injection reduced major adverse cardiovascular events by 20% in obese or overweight patients without diabetes, further bolstering the case for more widespread

August 9, 2023

How has the prevalence of psychological distress in the adult population of England changed since 2020?

Researchers estimated patterns of psychological distress.

July 10, 2023

In Conversation: Joanna Kempner, Author of “Psychedelic Outlaws: The Movement Revolutionizing Modern Medicine” – Psychedelic Alpha

Longstaff: It seems a case then with standards, particularly when it comes to the individual researchers and those backing them, they have to show a

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.